Clovis Oncology, Inc. CLVSQ

Market cap
$14.2M
P/E
0.0×
Growth Flags show if company had growth for consecutive years
Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21
P/E ratio
0.00 0.00 0.00 0.00 0.00 0.00
P/S ratio
0.00 55.98 9.80 3.93 2.46 2.10
P/FCF ratio
0.00 0.00 0.00 0.00 0.00 0.00
P/Operating CF
(30.23) (47.39) (11.30) (8.01) (7.22) (7.57)
P/B ratio
0.00 8.45 6.38 0.00 0.00 0.00
Price to Tangible BV
0.00 10.99 29.72 0.00 0.00 0.00
EV/Sales
0.00 50.91 10.38 6.65 4.71 5.30
EV/EBITDA
0.00 0.00 0.00 0.00 0.00 0.00
EV/Operating CF
(6.25) (10.83) (2.71) (2.94) (3.06) (4.02)
EV/FCF
(6.24) (10.66) (2.30) (2.78) (2.97) (3.86)
Quick Ratio
4.06 6.99 4.24 2.38 1.44 1.36
Current Ratio
4.26 7.69 4.55 2.75 1.68 1.58
Net Debt/EBITDA
(0.06) 1.11 (0.17) (1.06) (1.27) (2.21)
Debt/Assets
77.11% 41.41% 66.76% 102.32% 100.73% 130.84%
Debt/Equity
(77.36) 0.83 3.94 (3.93) (3.84) (2.22)
Asset Turnover
0.00 0.10 0.12 0.19 0.26 0.28
Operating CF/Net income
0.76 0.75 0.99 0.81 0.68 0.74
Capex/Depreciation
(0.01) (0.99) (7.91) (2.06) (0.78) (0.03)
Interest Coverage
0.00 0.00 0.00 0.00 0.00 0.00
ROE
(235.10%) (190.33%) (143.16%) 2,881.99% 221.75% 120.90%
ROA
(64.78%) (62.99%) (46.04%) (52.23%) (57.91%) (49.06%)
ROIC
(2,059.94%) (137.10%) (102.86%) (109.91%) (89.52%) (71.85%)
Return on Tangible Assets
(159.97%) (63.05%) (77.79%) (161.03%) (267.57%) (333.04%)
Average Days of Receivables
566.22 40.64 49.32 52.48 58.82 65.93
Research and Development Expense of Revenue
321,960.26% 256.70% 242.53% 198.00% 156.64% 125.44%
Selling, General and Administrative Expense of Revenue
52,219.23% 250.23% 184.28% 127.81% 99.62% 86.32%
Intangible Assets out of Total Assets
0.21 0.12 0.13 0.19 0.21 0.26
Share Based Compensation of Revenue
51,020.51% 80.54% 51.46% 37.97% 30.87% 17.11%
Graham Net Nets
(0.05) 0.08 (0.15) (0.85) (1.12) (1.77)
Graham Number
4.39 0.00 0.00 23.25 13.73 11.20
Earnings Yield
(21.12%) (11.34%) (39.37%) (71.24%) (92.71%) (85.24%)
Free Cash Flow Yield
(16.18%) (8.53%) (46.01%) (60.93%) (64.52%) (65.28%)
Revenue per Share
0.00 1.18 1.83 2.65 1.95 1.29
Operating CF per Share
(6.93) (5.55) (7.03) (6.01) (3.00) (1.70)
Capex per Share
(0.02) (0.09) (1.23) (0.35) (0.10) 0.00
Free Cash Flow per Share
(6.95) (5.63) (8.26) (6.36) (3.10) (1.70)
Cash per Share
6.92 11.98 9.99 5.51 2.85 1.24
Shareholders Equity per Share
(0.09) 7.81 2.81 (3.23) (1.88) (2.41)
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
(0.09) 7.81 2.81 (3.23) (1.88) (2.41)
Free Cash Flow
(267.38) (265.01) (430.24) (342.38) (261.08) (196.37)
Working Capital
213.81 545.42 446.55 233.38 125.90 72.87
Capital Expenditures
(0.70) (4.10) (64.24) (18.76) (8.35) (0.31)
Net Current Asset Value
(88.78) 259.35 (144.79) (477.39) (453.47) (553.59)
EV/EBIT
0.00 0.00 0.00 0.00 0.00 0.00
Capex to Sales
8.99 0.07 0.67 0.13 0.05 0.00
Net Profit Margin
(447,611.54%) (624.02%) (385.80%) (280.01%) (224.41%) (177.82%)
Price to Operating Income
0.00 0.00 0.00 0.00 0.00 0.00
Other line items
Depreciation/Fixed assets
24.12 1.03 0.31 0.60 0.89 1.67
Cash ROIC
(49.87%) (21.44%) (31.58%) (41.97%) (38.30%) (41.93%)
Accounts Receivable Turnover
0.02 17.62 10.00 8.55 6.99 5.57
Accounts Payable Turnover
0.01 0.90 1.01 1.14 1.40 1.44
Inventory Turnover
0.00 0.31 0.81 1.29 1.44 1.75
Average Days of Payables
56,898.29 471.05 471.54 339.23 235.87 256.72
Days of Inventory on Hand
0.00 855.45 447.64 279.06 271.41 128.68
Average Receivables
4.17 3.15 9.54 16.73 23.54 26.69
Average Payables
11.09 13.03 21.83 30.38 29.46 27.00
Average Inventory
— 37.52 27.29 26.80 28.62 22.20
Average Assets
538.97 549.89 799.40 766.58 637.58 539.19
Average Common Equity
148.51 182.00 257.05 (13.89) (166.50) (218.79)

Fold the line items

Columns are period end dates